정밀 정신의학 시장 규모, 점유율, 동향 분석 보고서 : 서비스 종류별, 기술별, 치료 분야별, 최종사용자별, 지역별, 부문별 예측(2025-2033년)

Precision Psychiatry Market Summary

The global precision psychiatry market size was estimated at USD 825.6 million in 2024 and is projected to reach USD 2,858.0 million by 2033, growing at a CAGR of 14.91% from 2025 to 2033. The market growth is driven by the rising prevalence of mental health disorders, increasing demand for personalized treatment approaches, genomics and biomarker research advancements, and growing adoption of artificial intelligence (AI) and digital health tools to improve diagnostic accuracy and treatment outcomes.

Global Precision Psychiatry Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global precision psychiatry market based on service type, technology, therapeutic area, end-user, and region:

• Service Type Outlook (Revenue, USD Million, 2021 - 2033)
• Genetic Testing
• Biomarker Analysis
• Data Analytics & Interpretation Services
• Others
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunoassay
• Mass Spectrometry
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Depression and Anxiety Disorders
• Schizophrenia and Psychotic Disorders
• Bipolar Disorder
• Substance Use Disorders
• Others
• End-user Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics
• Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Service Type
  • 1.1.2. Technology
  • 1.1.3. Therapeutic Area
  • 1.1.4. End User
• 1.2. Market Definitions
• 1.3. Information analysis
• 1.4. Market therapeutic area & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Others
• 1.7. Information or Data Analysis
• 1.8. Market Therapeutic Area & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. High burden of mental health disorders
    • 3.3.1.2. Advances in genomics and biomarkers
• 3.4. Market Restraint Analysis
  • 3.4.1.1. Data privacy, ethical, and regulatory challenges
  • 3.4.1.2. Limited clinical validation and integration into practice
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Service Type Business Analysis

• 4.1. Service Type Segment Dashboard
• 4.2. Global Precision Psychiatry Market: Service Type Movement Analysis
• 4.3. Global Precision Psychiatry Market Size & Trend Analysis, by Service Type, 2021 to 2033 (USD Million)
• 4.4. Genetic Testing
  • 4.4.1. Genetic Testing Market, 2021 - 2033 (USD Million)
• 4.5. Biomarker Analysis
  • 4.5.1. Biomarker Analysis Market, 2021 - 2033 (USD Million)
• 4.6. Data Analytics & Interpretation Services
  • 4.6.1. Data Analytics & Interpretation Services Market, 2021 - 2033 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Global Precision Psychiatry Market: Technology Movement Analysis
• 5.3. Global Precision Psychiatry Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
• 5.4. Next-Generation Sequencing (NGS)
  • 5.4.1. Next-Generation Sequencing (NGS) Market, 2021 - 2033 (USD Million)
• 5.5. Polymerase Chain Reaction (PCR)
  • 5.5.1. Polymerase Chain Reaction (PCR) Market, 2021 - 2033 (USD Million)
• 5.6. Immunoassay
  • 5.6.1. Immunoassay Market, 2021 - 2033 (USD Million)
• 5.7. Mass Spectrometry
  • 5.7.1. Mass Spectrometry Market, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Therapeutic Area Business Analysis

• 6.1. Therapeutic Area Segment Dashboard
• 6.2. Global Precision Psychiatry Market: Therapeutic Area Movement Analysis
• 6.3. Global Precision Psychiatry Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
• 6.4. Depression and Anxiety Disorders
  • 6.4.1. Depression and Anxiety Disorders Market, 2021 - 2033 (USD Million)
• 6.5. Schizophrenia and Psychotic Disorders
  • 6.5.1. Schizophrenia and Psychotic Disorders Market, 2021 - 2033 (USD Million)
• 6.6. Bipolar Disorder
  • 6.6.1. Bipolar Disorder Market, 2021 - 2033 (USD Million)
• 6.7. Substance Use Disorders
  • 6.7.1. Substance Use Disorders Market, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End User Business Analysis

• 7.1. End User Segment Dashboard
• 7.2. Global Precision Psychiatry market: End User Movement Analysis
• 7.3. Global Precision Psychiatry Market Size & Trend Analysis, by End User, 2021 to 2033 (USD Million)
• 7.4. Hospitals & Clinics
  • 7.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
• 7.5. Clinical Laboratories
  • 7.5.1. Clinical Laboratories Market, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Global Precision Psychiatry Market Share By Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. North America Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. Mexico Precision Psychiatry Market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Germany Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. UK Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. France Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Italy Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Spain Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway Precision Psychiatry Market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. South Korea Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Australia Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Thailand Precision Psychiatry Market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Argentina Precision Psychiatry Market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE Precision Psychiatry Market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait Precision Psychiatry Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Invitae Corporation
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Myriad Genetics
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Polaris Genomics
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. GeneDx
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Genomind
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. CNSDose
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. MedGenome
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. LabCorp
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. GeneHealth Global Research & Diagnostics
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Quest Diagnostics
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives